During his remaining tenure, he will continue to serve as CEO until a successor is named and will work to ensure a smooth and effective leadership transition for GPhA’s members, employees and stakeholders. Neas is leaving GPhA to explore entrepreneurial opportunities and to work on critical issues such as nonpartisan electoral reform.
“It has been an honor and a pleasure to work with my GPhA colleagues to help ensure access to safe and affordable medicines, which save patients and the health care system hundreds of billions of dollars annually. Over the past 12 months I have been talking to a number of board members and staff about the next chapter in my life. This joint decision will allow the GPhA board and me to execute a smooth leadership transition and allow me the time to explore leadership opportunities that have been presented to me regarding nonpartisan electoral reform and various entrepreneurial ventures in affordable health care,” commented Neas.
“I am especially proud of the exceptional GPhA team that has been built and how together we have achieved numerous legislative victories; protected the historic Hatch-Waxman Act; promoted future access to biosimilar medicines at the state, national and international levels; and enhanced our relationships with the FDA, Republican and Democratic members of Congress, and the executive branch.”
GPhA chairman Craig Wheeler, who also serves as president and CEO of Momenta Pharmaceuticals, noted that Neas brought his leadership to GPhA during a challenging period for the generic drug industry.
GPhA has begun a search for a new CEO. Neas will be available through spring of 2016 to advise new leadership.